The efficacy of serial serum amyloid A measurements for diagnosis and follow-up of necrotizing enterocolitis in premature infants

2010 ◽  
Vol 26 (8) ◽  
pp. 835-841 ◽  
Author(s):  
Merih Çetinkaya ◽  
Hilal Özkan ◽  
Nilgün Köksal ◽  
Okan Akacı ◽  
Taner Özgür
Keyword(s):  
Necrotizing Enterocolitis ◽  
Premature Infants ◽  
Serum Amyloid A ◽  
Serum Amyloid ◽  
Amyloid A ◽  
Serial Serum

scholarly journals Serum Amyloid A, Procalcitonin, Tumor Necrosis Factor-α, and Interleukin-1βLevels in Neonatal Late-Onset Sepsis

2008 ◽  
Vol 2008 ◽  
pp. 1-7 ◽  
Author(s):  
Birsen Ucar ◽  
Bilal Yildiz ◽  
M. Arif Aksit ◽  
Coskun Yarar ◽  
Omer Colak ◽  
...  
Keyword(s):  
Serum Amyloid A ◽  
Late Onset ◽  
Serum Amyloid ◽  
Amyloid A ◽  
Late Onset Sepsis ◽  
Sepsis Score ◽  
Reliable Marker ◽  
Factor Α ◽  
Necrosis Factor

Background. Sepsis is an important cause of mortality in newborns. However, a single reliable marker is not available for the diagnosis of neonatal late-onset sepsis (NLS). The aim of this study is to evaluate the value of serum amyloid A (SAA) and procalcitonin (PCT) in the diagnosis and follow-up of NLS.Methods. 36 septic and healthy newborns were included in the study. However, SAA, PCT, TNF-α, IL-1β, and CRP were serially measured on days 0, 4, and 8 in the patients and once in the controls. Töllner's sepsis score (TSS) was calculated for each patient.Results. CRP, PCT, and TNF-αlevels in septic neonates at each study day were significantly higher than in the controls (P=.001). SAA and IL-1βlevels did not differ from healthy neonates. The sensitivity and specificity were 86.8% and 97.2% for PCT, 83.3% and 80.6% for TNF-α, 75% and 44.4% for SAA on day 0.Conclusion. Present study suggests that CRP seems to be the most helpful indicator and PCT and TNF-αmay be useful markers for the early diagnosis of NLS. However, SAA, IL-1β, and TSS are not reliable markers for the diagnosis and follow-up of NLS.

scholarly journals Serum Amyloid A Protein as a Potential Biomarker Useful in Monitoring the Course of COVID-19 : A Retrospectively Studied

2020 ◽  
Author(s):  
Ying Zhang ◽  
Donglian Wang ◽  
Minjie Lin ◽  
Tong Sun ◽  
Jiaxi Chen ◽  
...  
Keyword(s):  
Serum Amyloid A ◽  
Clinical Course ◽  
Serum Amyloid ◽  
Rank Test ◽  
Blood Collection ◽  
Paired Data ◽  
Amyloid A ◽  
Potential Biomarker ◽  
Serum Amyloid A Protein

Abstract Background: Serum Amyloid A (SAA) is an acute-phase reactant downstream of the pro-inflammatory cytokines released during virus infection. However, the role of this inflammatory marker in SARA-CoV-2 infection is yet to be elucidated. Here, we explored the potential use of SAA in serum as a biomarker for monitoring the clinical course of COVID-19 patients.Methods: The subjects included 95 COVID-19 patients discharged from the hospital with acute and / or convalescent phases data, among them 69 patients had paired data. Mann-Whitney U statistics and Wilcoxon signed-rank test were used to compare SAA level in the acute and convalescent phases. A subgroup of COVID-19 patients (n=9) participated in a follow-up examination with repeated blood collection reach five times during the hospitalization. The correlations of SAA levels with laboratory testing were then analyzed using the Spearman test.Results: The results of the data analysis show that the media SAA levels at acute phases were significantly higher (P < 0.05) compared to that at baseline. Furthermore, ascensional range of SAA were associated with the degree of COVID-19 severity. Media SAA levels at convalescent phases were significantly decreased (P < 0.05) compared to that at acute phases. The same phenomenon was seen in patients with and without comorbidities and with fever patients except without fever patients. Furthermore, The SAA concentration change in 9 COVID-19 patients of longitudinal follow-up along with the CT score and SARS-CoV-2 nucleic acid change. In the course of the disease, SAA changes were greater than CRP, lymphocytes, and neutrophils.Conclusions: The serum SAA levels were found to be significantly correlated with impending course of the COVID-19, and may serve as a useful biomarker to monitor the complicated clinical course of the disease.

scholarly journals Serum amyloid-A levels in neonatal necrotizing enterocolitis

2011 ◽  
Vol 25 (4) ◽  
pp. 233-237 ◽  
Author(s):  
Zeynep Eras ◽  
Suna Oğuz ◽  
Evrim Alyamac Dizdar ◽  
Fatma Nur Sari ◽  
Uğur Dilmen
Keyword(s):  
Necrotizing Enterocolitis ◽  
Serum Amyloid A ◽  
Serum Amyloid ◽  
Amyloid A ◽  
Neonatal Necrotizing Enterocolitis

scholarly journals The effectiveness of serum amyloid a for prediction of neonatal cholestasis associated with parenteral nutrition in premature infants

2019 ◽  
Vol 61 (1) ◽  
pp. 26
Author(s):  
Hilal Özkan ◽  
Nilgün Köksal ◽  
Pelin Doğan ◽  
İpek Güney-Varal ◽  
Onur Bağcı ◽  
...  
Keyword(s):  
Parenteral Nutrition ◽  
Premature Infants ◽  
Serum Amyloid A ◽  
Serum Amyloid ◽  
Neonatal Cholestasis ◽  
Amyloid A

scholarly journals Prognostic value of serum amyloid A in patients with COVID-19

2020 ◽  
Author(s):  
Li Cheng
Keyword(s):  
Prognostic Value ◽  
Serum Amyloid A ◽  
Virus Disease ◽  
Medical Data ◽  
Serum Amyloid ◽  
Survival Group ◽  
Amyloid A ◽  
The Difference ◽  
Higher Sensitivity

Abstract Objective: To investigate the prognostic value of serum amyloid A (SAA) in the patients with Corona Virus Disease 2019(COVID-19). Methods The medical data of 89 COVID-19 patients admitted to Renmin Hospital of Wuhan University from January 3, 2020 to February 26, 2020 were collected. 89 cases were divided into survival group (53 cases) and non-survival group (36 cases) according to the results of 28-day follow-up. The SAA levels of all patients were recorded and compared on 1day after admission (before treatment) and 3day, 5day, 7day after treatment. The ROC curve was drawn to analyze the prognosis of patients with COVID-19 by SAA. Results: The difference of comparison of SAA between survival group and non-survival group before treatment was not statistically significant, Z1 = -1.426, P = 0.154. The Z1 values ​​of the two groups of patients at 3d, 5d, 7d after treatment were -5.569, -6.967, and -7.542, respectively. The P values were all less than 0.001, and the difference was statistically significant. The ROC curve results showed that SAA has higher sensitivity to prognostic value for death, the AUC area of 3d, 5d, 7d, which were 80.6%, 97.2%, 86.1%, and 96.1%, respectively. Conclusion: SAA can be used as a death predictor of the prognosis in patients with COVID-19.

Sign in / Sign up

Export Citation Format

Share Document